Business Wire

ATRC

12.2.2024 15:12:30 CET | Business Wire | Press release

Share
UAE's ATRC Launches Global Tech R&D Platform at WGS 2024: Allocates US$200 Mn Fund to Accelerate Innovation for Developing Nations

In a landmark announcement on Day 1 of the World Governments Summit (WGS) 2024, Abu Dhabi’s Advanced Technology Research Council (ATRC) unveiled a pioneering initiative aimed at facilitating global access to cutting-edge technology solutions. The newly launched ‘ATRC Global Tech R&D Platform’ serves as a channel for countries worldwide to tap into the UAE's technological expertise to address their unique challenges.

As the driving force behind Abu Dhabi and the wider UAE's advanced research and development (R&D) ecosystem, this initiative underscores ATRC's commitment to fostering inclusive growth and global prosperity. In an era of rapid technological transformation, the platform seeks to bridge technology gaps experienced by nations worldwide by offering tailored solutions to their pressing needs.

To initiate applications through the platform, ATRC is allocating US$200 million in funding to accelerate innovation, particularly for emerging and developing nations. By committing to absorb resource and research costs, the funding facilitates the development of sophisticated technology solutions, empowering these nations to keep pace with the latest advancements.

The ATRC Global Tech R&D Platform invites applications from governments, organizations, and eligible stakeholders all over the world, prioritizing collaboration, and inclusivity. Through a rigorous evaluation process, initiatives aligned with the platform's mission will receive support in six priority sectors: Aerospace and Space; Food and Agriculture; Healthcare; Safety and Security; Sustainability, Environment, and Energy; and Transport.

H.E. Faisal Al Bannai, Secretary General of ATRC, underscores the profound global impact of the initiative, stating: "Our commitment is to empower every nation with the means to thrive in this technology-driven world. ATRC stands ready to partner with countries worldwide, leveraging our expertise in technology to address their challenges and drive collective progress in the AI-driven era."

Over the span of almost four years, ATRC has developed a robust R&D ecosystem, with over 850 researchers from more than 70 countries. It has built an entire ecosystem that systematically supports every critical stage of a technology’s development journey. Its entity ASPIRE crowdsources global talent through grand challenges and global competitions and identifies technology gaps with its clients. The Technology Innovation Institute (TII) is focused on applied research with intentional outcomes and houses its leading researchers and scientists, while VentureOne commercializes its solutions, taking R&D products and services from lab to market.

ATRC offers a spectrum of capabilities spanning quantum and AI, autonomous robotics, and cryptography, as well as advanced materials, propulsion, and space – guiding technology needs from ideation to innovation.

From identifying an entity’s tech pain point to developing bespoke R&D solutions, ATRC orchestrates the complete lifecycle of technology advancement for companies and countries that need support. Situated at the global crossroads, it extends its reach to entities worldwide, facilitating innovation on a truly global scale.

Al Bannai is set to address a plenary session at the World Governments Summit, highlighting his views on AI’s evolution and emerging opportunities.

Dr. Ray O. Johnson, CEO of ATRC’s global applied research arm, TII, expressed optimism about the fund's potential to catalyze innovation, and said: "Through this platform, we will help identify untapped innovation around the world, unleashing the power of transformative technologies, and sparking economic growth."

ATRC is calling on nations to collaborate and contribute to the global technological landscape. For further details on the ATRC Tech R&D Fund, applicants can contact the Council via ASPIRE, at aspireuae.ae.

“We’re here to identify technology gaps and facilitate sophisticated solutions that countries may need to explore for a resilient future”, said Stephane Timpano, CEO of ASPIRE.

In a similar stance to support the wider adoption of advanced technologies, last year, the Technology Innovation Institute (TII) was among the first to open-source its world ranking large language model, Falcon 40B under the Apache 2.0 license – royalty-free.

*Source: AETOSWire

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240212472252/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release

Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye